Skip to main content
Livermore
Livermore
ZHEN

Paradigm Biocapital Advisors LP

SEC CIK
0001855655
Latest filing
Aug 14, 2026

Holdings in Q1 2024

Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.

Institution overview
Positions
34
+5 vs. Q4 2023
Portfolio value
$2.84B
+$707.0M (+33.1%) vs. Q4 2023
Filed
May 15, 2024
SEC
Holdings of Paradigm Biocapital Advisors LP in Q1 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
NUVLNuvalent, Inc.COM4,177,830$313.7M11.0%+319,822+8.3%AddedHistory
ACLXArcellx, Inc.COMMON STOCK3,818,095$265.5M9.3%+159,471+4.4%AddedHistory
ARGXArgenx SESPONSORED ADR552,120$217.4M7.7%+129,543+30.7%AddedHistory
IRONDisc Medicine, Inc.COM2,389,902$148.8M5.2%+4,045+0.2%AddedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM3,124,749$146.3M5.1%+811,830+35.1%AddedHistory
SRPTSarepta Therapeutics, Inc.COM1,078,346$139.6M4.9%+1,078,346NewHistory
IMCRImmunocore Holdings plcADS1,787,176$116.2M4.1%+333,293+22.9%AddedHistory
LEGNLegend Biotech CorpSPONSORED ADS1,982,006$111.2M3.9%+87,362+4.6%AddedHistory
ARVNArvinas, Inc.COM2,614,935$107.9M3.8%+1,683,632+180.8%AddedHistory
XENEXenon Pharmaceuticals Inc.COM2,484,874$107.0M3.8%+357,474+16.8%AddedHistory
TARSTarsus Pharmaceuticals, Inc.COM2,863,406$104.1M3.7%+1,838,406+179.4%AddedHistory
CERECerevel Therapeutics Holdings, Inc.COM2,330,508$98.5M3.5%00.0%UnchangedHistory
RVMDRevolution Medicines, Inc.COM2,914,975$93.9M3.3%+2,914,975NewHistory
OLMAOlema Pharmaceuticals, Inc.COM7,903,600$89.5M3.1%00.0%UnchangedHistory
VRDNViridian Therapeutics, Inc.COM5,031,420$88.1M3.1%+236,932+4.9%AddedHistory
PCVXVaxcyte, Inc.COM1,239,995$84.7M3.0%+1,239,995NewHistory
ALPNAlpine Immune Sciences, Inc.COM2,121,163$84.1M3.0%−1,055,580−33.2%ReducedHistory
BCYCBicycle Therapeutics PLCSPONSORED ADS3,246,759$80.8M2.8%−460,242−12.4%ReducedHistory
ASNDAscendis Pharma A/SSPONSORED ADR507,952$76.8M2.7%+156,252+44.4%AddedHistory
KURAKura Oncology, Inc.COM3,135,387$66.9M2.4%+1,872,559+148.3%AddedHistory
EWTXEdgewise Therapeutics, Inc.COM2,446,373$44.6M1.6%+2,446,373NewHistory
AUTLAutolus Therapeutics plcSPON ADS6,425,803$41.0M1.4%−6,185,532−49.0%ReducedHistory
YMABY-mAbs Therapeutics, Inc.COM2,233,610$36.3M1.3%+2,233,610NewHistory
IMTXImmatics N.V.SHS2,818,908$29.6M1.0%+682,569+32.0%AddedHistory
IMVTImmunovant, Inc.COM799,054$25.8M0.9%+799,054NewHistory
CGEMCullinan Therapeutics, Inc.COM1,348,015$23.0M0.8%+1,348,015NewHistory
APGEApogee Therapeutics, Inc.COM330,000$21.9M0.8%+330,000NewHistory
CMPSCOMPASS Pathways plcSPONSORED ADS2,390,988$19.9M0.7%+125,000+5.5%AddedHistory
VORVor Biopharma Inc.COM6,457,293$15.3M0.5%00.0%UnchangedHistory
ZNTLZentalis Pharmaceuticals, Inc.COM944,917$14.9M0.5%+544,917+136.2%AddedHistory
AGIOAgios Pharmaceuticals, Inc.COM400,000$11.7M0.4%+400,000NewHistory
CRBUCaribou Biosciences, Inc.COM2,172,620$11.2M0.4%−751,231−25.7%ReducedHistory
CRGXCARGO Therapeutics, Inc.COM147,959$3.30M0.1%−185,374−55.6%ReducedHistory
KYTXKyverna Therapeutics, Inc.COM50,000$1.24M<0.1%+50,000NewHistory

Sold out since Q4 2023 (5)

Positions held at the end of Q4 2023 that are gone from this filing.

Positions of Paradigm Biocapital Advisors LP sold out since Q4 2023
SecurityClassShares in Q4 2023Value in Q4 2023% of portfolio in Q4 2023History
MRTXMirati Therapeutics, Inc.COM1,543,116$90.7M4.2%History
AMAMAmbrx Biopharma, Inc.COM4,352,689$62.0M2.9%History
TGTXTG Therapeutics, Inc.COM2,171,419$37.1M1.7%History
ZLABZai Lab LtdADR1,091,779$29.8M1.4%History
JBIOJade Biosciences, Inc.COM143,235$3.24M0.2%History